TrialCurvePRESERVE-003: reconstructed Kaplan–Meier curves
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Med. 2026 Mar 27;32(6):2245–53. doi: 10.1038/s41591-026-04323-8 |
|---|---|
| DOI | 10.1038/s41591-026-04323-8 |
| Registry | NCT05671510 |
| Phase | Phase 3 |
| Conditions | Non Small Cell Lung Cancer |
| Interventions | Gotistobart, Docetaxel |
| Sponsor | OncoC4, Inc. |
| Enrolment | 630 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival (OS) — Patients with sqNSCLC
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Gotistobart not reached; Docetaxel 10.0 months. Survival at 6 months: Gotistobart 75%; Docetaxel 72%. Hazard ratio Gotistobart vs Docetaxel 0.47 (95% CI 0.26–0.87).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Gotistobart | 45 | 17 | not reached |
| Docetaxel | 42 | 27 | 10.0 |
- Gotistobart vs Docetaxel: reconstructed HR 0.47 (95% CI 0.26–0.87)
Landmark survival (reconstructed)
| Time | Gotistobart | Docetaxel |
|---|---|---|
| 6 mo | 74.8% | 71.8% |
| 12 mo | 63.1% | 32.1% |
| 18 mo | 60.4% | — |
Checks against the published figure
- Docetaxel median: printed 10, reconstructed 9.95 pass
- Gotistobart events: printed 17, reconstructed 17 pass
- Gotistobart n: printed 45, reconstructed 45 pass
- Docetaxel events: printed 28, reconstructed 27 pass
- Docetaxel n: printed 42, reconstructed 42 pass
- hazard ratio (direction inferred): printed 0.46, reconstructed 0.471 pass
Progression-free survival (PFS, investigator assessment) — Patients with sqNSCLC
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Gotistobart 2.4 months; Docetaxel 2.6 months. Survival at 6 months: Gotistobart 33%; Docetaxel 13%. Hazard ratio Gotistobart vs Docetaxel 0.73 (95% CI 0.44–1.21).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Gotistobart | 45 | 34 | 2.4 |
| Docetaxel | 42 | 33 | 2.6 |
- Gotistobart vs Docetaxel: reconstructed HR 0.73 (95% CI 0.44–1.21)
Landmark survival (reconstructed)
| Time | Gotistobart | Docetaxel |
|---|---|---|
| 3 mo | 45.6% | 42.2% |
| 6 mo | 32.9% | 13.2% |
| 9 mo | 25.3% | 3.3% |
| 12 mo | 25.3% | — |
| 15 mo | 13.6% | — |
Checks against the published figure
- Gotistobart median: printed 2.4, reconstructed 2.38 pass
- Docetaxel median: printed 2.6, reconstructed 2.55 pass
- Gotistobart events: printed 34, reconstructed 34 pass
- Gotistobart n: printed 45, reconstructed 45 pass
- Docetaxel events: printed 34, reconstructed 33 pass
- Docetaxel n: printed 42, reconstructed 42 pass
- hazard ratio (direction inferred): printed 0.69, reconstructed 0.731 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- ETER701: Overall survival; Progression-free survival (PFS)
- Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials